4.2. Genome-Wide Associations and Functional Validation Studies Reveal Genetic Susceptibility and Neurobiological Mechanisms of Substance Use Disorder

Given the high heritability of SUD, enormous efforts have been taken to resolve genetic variations that may cause vulnerability to the disease. In addition, it has been shown that treatment response is highly dependent on genetic variation in genes that regulate the synthesis, metabolism, and transport of major neurotransmitters involved in reward behaviors and drug use. Exploring the mechanisms of the strong link between treatment responsiveness and genetic profile may thereby improve the efficacy of pharmacotherapies for SUD (Heilig et al. 2011).

Genome-wide association studies (GWAS) measure and analyze DNA sequence variation across the entire genome to identify genetic risk factors for complex diseases. In large genetic association studies, several important factors determine the power of this approach to detect important risk variants. The number of subjects examined, number of genetic markers compared between subjects, the specificity and definition of case vs. control subjects, etc. are all critical to the impact of these studies. Ultimately, the goal of GWAS is to exploit such results to improve predictions about individuals and populations at higher risk for developing a given disease. From GWAS datasets, researchers can also establish which molecular systems are critical to disease susceptibility and progression. These data in turn can be used in the development of prevention and treatment strategies – including those based on tailoring specific treatments to individuals based upon genotype. Several classes of genes have been elucidated as being important to the genetic component of SUD through GWAS (Table 1). Overall, genes identified in GWAS as being related to SUD tend to cluster around components of drug mechanisms of action, as well as factors associated with neuroplasticity: gene components of extracellular proteins, cytoskeleton/cell adhesion, cell signaling, and gene expression regulation. In the next section, we will examine an example of a genetic risk variant for SUD identified with GWAS and the series of studies that applied molecular genetic techniques to validate and characterize this polymorphism in vitro and in animal models.

4.3. GWAS Identified a nAChR Subunit Risk Variant Associated with Nicotine Dependence

The first addiction GWAS reports focused on nicotine dependence (Bierut et al. 2006; Saccone et al. 2006). Comparing 1,050 cases defined by FTND scores for nicotine dependence vs. 879 controls, these studies identified significant associations for variants in a region on human chromosome 15 encoding the α3, α5, and β4 subunits of the nicotinic acetylcholine receptor (nAChR). Nicotine acts as a potent agonist for these nAChR ligand-gated ion channels, which are distributed in specific reward-related brain regions in varying combinations of subunits, each with diverse functional characteristics. The risk polymorphisms in these genes were found to increase probabilities for nicotine dependence (Bierut et al. 2006; Sherva et al. 2008). One of the identified variants, the non-synonymous SNP rs16969968 found in exon 5 of the α5 gene (α5SNP), causes an amino acid change (D398N). This SNP is fairly frequent in the general population, found in approximately 35% of Europeans and 50% of Middle Eastern populations (Saccone et al. 2006). In meta-analyses of human clinical populations, it has been associated with an increased risk for nicotine dependence, lung cancer, lower aversive experience to smoking, and increased cognitive enhancement after nicotine exposure (Saccone et al. 2006; Chen et al. 2015). Moreover, the haplotype carrying the rs16969968 risk allele has implications for cessation treatment success, with smokers at highest nicotine dependence risk being less likely to quit smoking overall but responding most effectively to pharmacologic treatments (Chen et al. 2015). These findings highlight the potential for personalized cessation treatments based upon genetic risk variants for nicotine dependence. However, the exact structural changes and resulting functional differences caused by this SNP could not be determined from simple genome associations. In the years following the discovery of this SNP, the connection between nicotine dependence and genetic variation at this locus has become the most widely replicated GWAS finding in the psychiatric disease literature, providing a particularly illustrative example of the variety of molecular genetic techniques that are applied to investigate genetic variants identified by human GWAS.

4.4. Molecular and Pharmacological Approaches Have Defined Roles for Genetic Polymorphisms in Substance Use Disorder Physiology

Candidate loci identified by GWAS provide valuable targets for mechanistic dissections in preclinical models. Once a genetic variant has been identified through GWAS, it is critical to determine if the polymorphism has an effect on the gene product’s expression or function. Once a definitive effect is identified, researchers can then use molecular genetic and pharmacological approaches to determine its specific role in the drug’s mechanism of action.

In vitro studies are those performed using molecules, cells, or organisms outside of their biological context and can be powerful tools for examining the ultimate effect of a SNP on a protein’s structure and function before investigations in more complex animal models. In the case of the CHRNA5 polymorphism, early in vitro studies utilized HEK cells to validate the effects of the rs16969968:G > A SNP and found that the amino acid variant confers a partial loss of function to the nAChR by reducing Ca²⁺ influx after nicotine-mediated activation, implying that the variant receptor desensitizes more quickly vs. its wild-type counterpart (Saccone et al. 2006; Kuryatov et al. 2011). While these studies provided critical validation of CHRNA5’s effect on receptor function, HEK cell lines are derived from human embryonic kidney cells grown in tissue culture and cannot recapitulate the cell-type-specific genetic architectures and proteomes of differentiated human neurons.

A more biologically relevant in vitro system has been made available with recent advances in induced pluripotent stem cells (hiPSCs), which have allowed researchers to create differentiated cell types with skin fibroblasts collected from a human patient. Differentiated cells from hiPSCs have the exact genome as the donor patient and thus can be utilized as a model cellular system. Recently, Deflorio et al. generated hiPSCs from individuals with and without polymorphisms in the nAChR α5 subunit and then differentiated them into midbrain dopaminergic (DA) neurons. By measuring the functional electrophysiological properties of wild-type (WT) vs. variant nAChRs expressed in these human DA neurons, the authors discovered that with this SNP, more nicotine and/or acetylcholine chloride is necessary to obtain the same downstream calcium influx in comparison to the wild-type receptor (Deflorio et al. 2016). Moving forward, this hiPSC system can be used in drug discovery approaches to further dissect dependence-related phenotypes and screen for compounds that interact specifically with human wild-type vs. polymorphic nAChRs (Collo et al. 2018). While in vitro studies are indispensable for probing the functional consequences of genetic variation identified in GWAS, they are performed in artificial systems isolated from the complexity of a biological context. Moreover, in disease modeling, the most valuable translational insights inform how a gene or gene variant impacts behavior. For this purpose, genetically engineered rodents are one of the most important means used to tease out functional roles for specific genes.

4.5. Animals: Behavioral Models of Substance Use Disorder

Animal models are critical for use in genetic manipulation experiments aimed at mechanistic investigation, which are currently impossible to perform in human subjects. Achieving face and construct validity for an animal model of psychiatric disease is one of the primary concerns when designing behavioral paradigms of SUD. However, the models for SUD described here are some of the most reproducible and useful for studying distinct aspects of the addiction cycle. Because the vast majority of animal studies for SUD have been conducted in rodents (i.e., mice and rats), we will focus on paradigms utilizing these species. It should be noted, however, that there are examples of investigations performed in nonhuman primates to analyze more complex behaviors, as well as research that has utilized more basic models, such as Drosophila, to examine conserved mechanisms of drug-taking behaviors (often with alcohol or cocaine). Drugs that have positive reinforcing effects in rodents and primates mirror closely with those that have high abuse potential in humans, including alcohol, cocaine, and heroin. Below, we will briefly describe a couple of the behavioral paradigms used to investigate SUD in rodents.

4.6. Use of Animal Models to Explore Genetic Polymorphisms Associated with Substance Use Disorder

In the case of nicotinic receptor variants identified in human GWAS studies, manipulation of these receptor subunit genes in rodents has greatly expanded our understanding of the neurobiology of nicotine addiction. One of the earliest genetic editing studies conducted for the CHRNA5 risk variant was the generation of a Chrna5 subunit knockout (KO) mouse, in which the gene for Chrna5 was silenced or excised from the germline. A KO mouse can give researchers clues into the overall function of a gene of interest and the effects of disrupting its protein product. A series of these studies showed that mice lacking the α5 subunit escalate their nicotine self-administration at high doses in comparison to normal control mice (Fowler et al. 2011; Morel et al. 2014), while wild-type animals appear to titrate the amount of nicotine self-administered to maintain a consistent dosage. Several brain regions involved in nicotine dependence have been evaluated for potential changes in function after disruption of the Chrna5 gene. Fowler et al. reported increased nicotine intake in mice with a null mutation in Chrna5. This effect was “rescued” in knockout mice by re-expressing wild-type α5 subunits in the medial habenula (MHb), a brain region associated with inhibition of rewarding signals during an aversive experience. Interestingly, knocking down the α5 subunit in the MHb did not change reinforcing effects of nicotine but did eliminate the MHb’s inhibitory brake on nicotine taking at high doses, which would otherwise be aversive.

Such KO and rescue studies yield invaluable insights into the overall function of a gene of interest and the role that it might play in producing a given phenotype. However, they cannot precisely address the consequences of constitutive expression of a specific SNP throughout development. Until recently, the available toolbox of rat genetics lacked the ability to easily introduce site-directed, heritable mutations into the genome to create KO or knock in (KI) rats. To this end, programmable molecular gene-editing systems have been developed in progressively accessible iterations, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short palindromic repeat)-associated protein 9 (Cas9) RNA-guided engineered nucleases (RGENs) (Kim and Kim 2014). These gene-editing machineries can be injected into single-cell rat embryos to induce sequence-specific double-strand breaks and the subsequent insertion of a transgene through homologous recombination. Recently, researchers were able to utilize the ZFN system to KO the WT nCHR5 subunit and replace it with the rs16969968:G > A SNP in rat germline, creating animals constitutively expressing the variant form of this subunit during development (Forget et al. 2018). The authors then ran WT vs. KO vs. α5SNP rats through a self-administration paradigm in order to determine the differential effects of manipulating this gene on nicotine taking behavior. Unlike the WT animals, the nCHR5 KO rats did not acquire self-administration of nicotine at the dose used in this study, which is consistent with previous reports in mice showing that KO animals require higher doses of nicotine to develop a learned response – suggesting the nCHR5 subunit is important for sensitivity to nicotine. At high nicotine doses, however, KO mice do show increased nicotine taking over WT mice. Interestingly in this study, the α5SNP rats were able to acquire nicotine taking at the lower dose of nicotine similarly to the WT rats, but unlike the WT condition, the α5SNP did not reduce their nicotine intake at high doses and were willing to exert more energy to obtain a nicotine infusion. These results demonstrate how different the resulting phenotype can be when a gene is knocked out vs. when the same gene with disease-relevant mutations is edited in.

These gene-editing strategies can be used to gain even more specific control of transgene expression by using systems like Cre recombinase in order to create cell-type-specific or inducible expression of the editing molecule in a certain brain region or cell type of interest. Cre recombinase is a protein that recognizes and mediates site-specific recombination between loxP site sequences. This unique property can be harnessed by inserting these loxP sites around a transgene of interest. When Cre recombinase is expressed in a cell containing these loxP sites, researchers can elicit gene deletion, insertion, translocation, and inversion depending on the location and orientation of the sites. The Cre/loxP recombination system has become an ideal tool for genetic manipulation in mammalian cells and genetically modified animal models. For example, Morel et al. utilized a Cre recombinase approach in order to investigate the role of the mutant nCHR5 subunit specifically in dopaminergic neurons in the mouse ventral tegmental area (VTA) (Morel et al. 2014). In this paper, the authors utilized the Cre recombinase system to re-express the α5SNP version of the subunit under control of the dopamine transporter (DAT), which resulted in a partial loss of nicotine-evoked receptor function and yielded intermediate behavioral and electrophysiological phenotypes compared with those of the α5 KO mice, suggesting that the α5 subunit has a critical role in defining the sensitivity of the VTA DA system to nicotine through its effects on raising the threshold for dopaminergic release in this brain region.

Taken together, these functional validation studies have helped to form a more complete picture of nAChRs subunit genetic variants and their role in nicotine addiction. In the case of smoking cessation, there are now three FDA-approved medications in existence: nicotine replacement therapy; varenicline – a partial agonist of the α4β2 nicotine receptors that produces less effects on dopamine release in comparison to nicotine; and bupropion, an atypical norepinephrine-dopamine reuptake inhibitor (NDRI) antidepressant and nicotinic receptor antagonist. Emerging evidence suggests that stratifying patients based on CHRNA5 genetic biomarkers may improve responsiveness to nicotine replacement therapy (Chen et al. 2015). For example, Chen et al. described two randomized cessation trials in which the efficacy of nicotine replacement therapy varied with rs16969968 genotype but not for varenicline treatment. This variant also contributes to increased risk for lung cancer and chronic obstructive pulmonary disease (Hung et al. 2008; Timofeeva et al. 2012), highlighting its association with heavier smoking and a lower likelihood of quitting. While there is equivocal evidence of an interaction between genotype and treatment efficacy, the CHRNA5 SNP is a known biomarker for difficulty in quitting smoking, and genotyping can help to identify individuals with CHRNA5 high-risk alleles, as they typically have an increased need for pharmacological cessation aids (Chen et al. 2015).

Finally, the α5-containing nAChRs impacted by CHRNA5 variation may represent an important target for medication development. Considering that CHRNA5 risk variants result in hypofunction of α5 nAChRs, novel pharmacological agents that enhance the activity of a5 nAChRs may decrease nicotine use by restoring appropriate cholinergic signals that mediate the aversive properties of nicotine. Moving forward, advances in methodological approaches will allow studies to leverage our current knowledge of CHRNA5 and other variants in order to better characterize their downstream effects toward improved treatments.

4.7. Transcriptomics and Substance Use Disorder

Persistent changes in gene expression drive neuroplastic maladaptations in the reward circuitry that underlie craving, drug-seeking, and relapse during SUD progression (Lüscher and Malenka 2011). For this reason, researchers have sought to outline the coordinated alterations in transcriptional programs that may precipitate aberrant synaptic plasticity in these cells. Moreover, GWAS results can be integrated and overlaid with transcriptomic data to reveal where SNPS and CNVs might be associated with gene expression changes in key brain regions implicated in reward learning. Much of the early work interrogating gene expression in clinical SUD and in animal models of addiction utilized real-time polymerase chain reaction or in situ hybridization in a priori, hypothesis-driven approaches to measure amounts of candidate genes in controls vs. cases – studies that corroborated the idea of transcriptional dysregulation in the reward system (Nikoshkov et al. 2005; Bach et al. 2014). More recently, transcriptomic analysis of the full complement of mRNA in a given tissue with next-generation sequencing techniques, such as RNA-seq, has provided researchers with greater insights into the coordinated networks of gene expression changes that may underlie SUD progression (Wolf 2010; Robison and Nestler 2011; Egervari et al. 2017).

In order to illustrate how profiling studies can validate and extend our understanding of genetic association findings, we will use the example of the OPRM1 gene, which encodes the human G-protein coupled mu opioid receptor (MOR). The MOR is responsible for mediating the rewarding effects of opioids. Numerous SNPs in the ORPM1 gene have been identified as associated with heroin addiction in candidate genome association studies (Nelson et al. 2014). Several years of work have used in vitro studies and mouse genetics to demonstrate that MOR represents the primary in vivo molecular target for both the most clinically useful (morphine) and most largely abused (heroin) opiates (Bond et al. 1998; Befort et al. 2001; Wang et al. 2001). MOR KO in mice abolishes both heroin and morphine CPP and self-administration (Becker et al. 2000; Contet et al. 2004). Targeted expression studies have shown that one of the most common SNPs in this locus, A118G, is a functional variant with deleterious effects on both mRNA and protein levels (Zhang et al. 2005). However, the transcriptional events downstream of reduced ORPM1 expression associated with this SNP were not well characterized. Sillivan et al. thus performed transcriptional microarray analyses on NAc from human patients dependent on heroin, a brain region involved in goal-directed behavior and reward processing (Sillivan et al. 2013), whereby they revealed evidence of dysregulated MOR signaling pathways in heroin abusers compared to controls. The authors then analyzed differentially expressed genes using pathway analyses and identified the ELK1 transcription factor as an important regulator of these genes. ELK1 is a known target of the ERK signaling pathway, which itself has been widely studied in cocaine-related dopaminergic signaling. Interestingly, ELK1 expression was found to also correlate with risk variants of ORPM1 in a dose-dependent manner, suggesting a link between ELK1-associated transcriptional programs and reduced expression of ORPM1. Furthermore, ELK1 expression correlates with the severity of heroin use in both human subjects and rat self-administration models of heroin abuse. ELK1 has also been implicated in the mechanisms of drug addiction to other substances besides heroin, including synthetic opioids, THC, and cocaine (Valjent et al. 2001). Several other studies have identified ELK1-regulated genes as being differentially expressed after drug exposures. For example, after ELK1 was identified in mechanistic and transcriptional studies of cocaine administration, Besnard et al. used a cell-penetrating peptide, named TAT-DEF-Elk-1 (TDE), to specifically inhibit ELK1 phosphorylation and the subsequent induction of plasticity-related genes. In doing so, they found that such inhibition reverses cocaine-induced increases in dendritic spine density and delays CPP for cocaine (Besnard et al. 2011). Together, these findings indicate ELK1 as a potential molecular target mediating cellular phenotypes in opioid addiction and highlight transcriptomics as a powerful tool in probing the mechanisms of SUD.

5.1. Histone Modifications

The basic unit of transcription (i.e., the nucleosome) is comprised of a protein/DNA complex composed of ~147 base pairs of double-stranded DNA wrapped around a core histone octamer containing two copies each of the histone proteins H2A, H2B, H3, and H4. Histones are small, highly alkaline proteins containing both globular domains and more flexible N- and C-terminal “tails” that can undergo posttranslational modifications in order to alter their structure and change the nature of their interactions with neighboring DNA. These tails are heavily modified by the covalent addition of acetyl, methyl, phospho, ubiquitin, and other chemical groups that affect their charge and/or how they interact with DNA-binding proteins. These modifications are placed by specialized enzymes termed “writers” that have highly specific motifs that recognize a combination of DNA sequence/amino acid position/histone modifications, and they are removed by equally specific “eraser” enzymes. Complex combinatorial “histone codes” are thus hypothesized to dictate which regions of DNA will be accessible to transcription factors, enhancers, silencers, and other regulatory factors. These histone marks provide a reversible, labile substrate for the aberrant neural plasticity observed in drug addiction. As SUD is expressed as an aberrant form of neural plasticity (Hyman et al. 2006), there has been much focus on examining potential epigenetic sources of gene regulation in drug addiction (LaPlant and Nestler 2011; Walker et al. 2015).

Over the past 10 years, many studies have demonstrated alterations in global, temporally defined histone modification states in the human and rodent brain in response to cocaine administration (Kumar et al. 2005; Maze et al. 2010; LaPlant and Nestler 2011). Similar phenomena have been observed for other drugs of abuse, including methamphetamine (Schmidt et al. 2012; Jayanthi et al. 2014) and morphine (Mashayekhi et al. 2012). Global levels of histone modifications can be evaluated using chromatin immunoprecipitation-sequencing (ChIP-seq) methods. ChIP-seq begins by cross-linking the DNA from a given cell population to all associated DNA-bound proteins and then using antibodies specific to a protein of interest to immunoprecipitate and sequence the stretches of DNA associated with that protein. These types of studies in animal models of SUD suggest that the presence of distinct histone modification marks at gene promoters (e.g., on H4 vs. H3) can encode the temporal progression of drug taking in the form of chromatin structural changes from acute to chronic exposures through relapse.

Manipulation of the enzymatic machineries responsible for depositing/removing these marks can yield insights into the regulatory mechanics of histone modification changes. For example, Maze et al. identified persistent decreases in levels of classical repressive H3 lysine methylation, as well as in the expression of the G9a K-methyl transferase, 24 h after cocaine administration, events that correlated with increased synaptic plasticity and the upregulation of a subset of plasticity-related genes (Maze et al. 2010). We subsequently used a series of regional-specific conditional manipulations of G9a in the mouse NAc to selectively knock down G9a in this brain region to directly determine its role in cocaine-induced neuronal plasticity and CPP behaviors. In doing so, we found that G9a downregulation increased dendritic spine plasticity of NAc neurons and enhanced preferences for cocaine, thereby establishing a crucial role for histone methylation in the long-term actions of cocaine (Maze et al. 2010). Interestingly, the example of G9a manipulation in animal models of cocaine taking also offers a demonstration of the complexities of interpreting different drug-related behavioral paradigms. Recently, it was shown that even though artificially reducing G9a in the NAc enhances cocaine CPP and overexpression reduces cocaine CPP, overexpression of G9a actually increased cocaine-seeking behavior in a different experimental paradigm, self-administration (Anderson et al. 2018). The authors also revealed the anxiogenic effect of G9a overexpression during the self-administration training, and overall these data highlight the importance of carefully defining the drug-related behavioral phenotype in question. These and many other studies have cemented a role of histone modifications in neural plasticity and SUD. However, many of the approaches used above measure and manipulate overall levels of a given histone modification across the genome but do not necessarily address the downstream effects of individual histone modification located at specific gene loci. Below, we discuss examples of new approaches that can be used to further examine the role of gene-specific deposition of histone modifications in the precipitation of molecular and behavioral effects caused by drug exposures.

Recent advances in gene targeting have allowed a more specific dissection of the role of histone modifications related to given phenotypes using engineered transcription factors, zinc finger proteins (ZFPs) (Snowden et al. 2002), and/or transcription activator-like effectors (TALEs) (Sanjana et al. 2012) that can be designed to recognize and bind to specific loci throughout the genome in order to deliver histone modifications directly to genes of interest in vivo. This gene-targeted approach makes it possible to directly examine the behavioral and biochemical consequences of various epigenetic marks in the context of drug exposures (Heller et al. 2014).

Recently, Heller et al. utilized this technique to investigate the role of a transcriptionally permissive modification, histone H3 lysine 9/14 acetylation (H3K9/14 ac), vs. a repressive mark, histone H3 lysine 9 dimethylation (H3K9me2), targeted specifically to the Cdk5 locus in NAc, a gene implicated in reward-related behaviors in this brain region. In doing so, they demonstrated increased cocaine-induced locomotor behaviors, as well as resilience to social stress, following activation of Cdk5 (Heller et al. 2016). Conversely, Cdk5 repression by H3K9me2 was found to attenuate both cocaine-induced locomotor behaviors and conditioned place preference (Heller et al. 2016). These data are especially compelling given that previous work has identified different behavioral responses upon Cdk5 overexpression vs. knockdown, demonstrating the importance of targeted epigenetic remodeling tools in studies of tunable molecular changes occurring in disease states.

5.2. DNA Methylation

Another important epigenetic modification that contributes to chromatin structure and accessibility is DNA methylation, which occurs when a methyl group is covalently added to a cytosine nucleotide (Jaenisch and Bird 2003). This modification is catalyzed by a family of enzymes called DNA methyltransferases (DNMTs). DNA methylation is often associated with targeted genomic silencing and closed heterochromatic genome regions. Methylation patterns are established and modified throughout development in tissue- and cell-type-specific configurations. In the past decade, accumulating evidence has implicated DNA methylation in learning, cognition, and neural plasticity in response to environmental cues, making it a key mechanism of interest in epigenetic regulation of SUD-related plasticity.

A range of studies have investigated levels of DNMTs in self-administration animal models of SUD, finding global changes in DNMT expression over temporally defined stages of self-administration. For example, immediately following the last session of cocaine taking, Dnmt3a was upregulated at an early time point of withdrawal (4 h after the last cocaine dose), followed by downregulation after 24 h (LaPlant et al. 2010). However, after 28 days of withdrawal following either cocaine IP injections or cocaine self-administration, Dnmt3a was upregulated in NAc, demonstrating long-lasting inductions of Dmnt3a expression and regulation of genes downstream of Dnmt3a activity. Furthermore, artificially manipulating levels of Dnmts – and/or associated methyl-binding proteins – via knockdown or overexpression in key reward-related brain regions have been found to affect addiction-related behaviors in rodent models. For example, MeCP2 is a reader protein for DNA methylation and is thought to act primarily as a transcriptional repressor through recruitment of histone deacetylases to methylated DNA (Bird 2002). MeCP2 is broadly implicated in addiction, as extended cocaine self-administration increases its expression in the dorsal striatum and other limbic regions, and genetic manipulations of (Im et al. 2010) MeCP2 levels alter addiction-related behaviors in rodents. Given that the machinery involved in placing and recognizing DNA methylation seems to be involved in the molecular changes related to addiction behaviors, efforts have been undertaken to use genome-wide approaches to examine genetic loci where DNA methylation is gained or lost during chronic exposures to psychoactive substances.

Recently, Kozlenkov et al. performed genome-wide bisulfite sequencing on orbitofrontal cortex (OFC) of heroin addicts who died of overdose. Importantly, this profiling study was performed on FACS-purified neuronal nuclei separated from glial cells, allowing the authors to determine cell-type-specific effects of heroin abuse on methylation (Kozlenkov et al. 2017). Using this approach, they identified hypermethylated regions in exons of synaptic plasticity genes enriched in glutamatergic, but not GABAergic, neuronal subtypes. Hypomethylated regions were preferentially found in promoter and enhancer regions of genes related to transcription factor activity and gene expression regulation. Altogether, these results concur with previous reports of reduced glutamatergic transmission in the frontal cortex observed in rodent models following drug exposures, and they highlight that DNA methylation changes in neurons are specific to targeted gene regions. These observations also suggest that DNA methylation may be recruited to different genic features or regulatory domains in the context of heroin use to influence aspects of transcription.

We thank the National Institutes of Health (DP1DA042078, R01MH116900, R21DA044767 to I.M.) for their gracious support of this work.